Associated tags: Synthetic, ASX, RCE, Pharmaceutical industry, FSE, Infection, Recce, Safety, Bacteria, Gram-negative bacteria, Vaccine, Virus, Male, Clinical trial, Patient, FDA, Sepsis, Degenerative disease, Pew, GAIN
Locations: UNITED STATES, EUROPE, JAPAN, CHINA, NEW ZEALAND, HONG KONG, VIETNAM, RADIUM, NEW SOUTH WALES, FLORIDA, SR, IV, AUD, COLORADO, SYDNEY, AU, AUSTRALIA, BARDA, US, WA
RCE,
ASX,
Recce,
Pharmacy,
Patent,
Family,
Treatment,
Genetically modified bacteria,
Infection,
Growth,
Pharmaceutical industry SYDNEY, Australia, May 08, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced the China National Intellectual Property Administration has formally granted Recce a new family two patent, “Copolymer and Method for Treatment of Bacterial Infection,” for its anti-infectives, with expiry in 2035.
Key Points:
- SYDNEY, Australia, May 08, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced the China National Intellectual Property Administration has formally granted Recce a new family two patent, “Copolymer and Method for Treatment of Bacterial Infection,” for its anti-infectives, with expiry in 2035.
- “We thank the China National Intellectual Property Administration for their recognition of the significant potential of Recce’s new class of anti-infectives,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
- “We are proud to have completed our portfolio of family two patents and now have coverage globally until at least 2035.”
This is the final of Recce’s wholly-owned patents granted for family two, with the Company now patent-protected in all major pharmaceutical markets globally.
- The Chinese patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), including their methods of manufacture, administration, and application to treat a broad range of common human infections.
Retrieved on:
Wednesday, April 17, 2024
FDA,
RCE,
Certification,
Food,
Quality control,
Ulcer,
ASX,
IND,
Patient,
Medicine,
Infection,
GMP,
Vaccine This week, the Company temporarily transported its manufacturing equipment from its Macquarie Park Facility to a third-party cleanroom-GMP facility, where it produced an increased quantity of 5,000 R327 doses under GMP, including fill and finish, the final step of the manufacturing cycle.
Key Points:
- This week, the Company temporarily transported its manufacturing equipment from its Macquarie Park Facility to a third-party cleanroom-GMP facility, where it produced an increased quantity of 5,000 R327 doses under GMP, including fill and finish, the final step of the manufacturing cycle.
- The manufacturing process is normally completed in-house, where the product is then transferred to a specialist clean room facility for GMP fill and finish.
- This marks a first for Recce’s full-spectrum manufacturing capability, which includes demonstrating the versatile, reproducible nature of its patented manufacturing process.
- Without GMP, it is impossible to be sure that every unit of medicine is of the same quality as the units tested in the laboratory.1
Retrieved on:
Wednesday, April 10, 2024
Urine,
FDA,
Congress,
Multi,
WHO,
Ecosystem,
Safety,
World Health Organization,
Blood,
Food,
Burn,
Poster,
Infection,
AMR,
Partnership,
Recce,
Escherichia coli,
Fungal infection,
Research,
Sputum,
BIO,
Development,
IND,
Pharmacology,
Defense,
Science,
Society,
MDR,
Clinical trial,
Annual general meeting,
Antimalarial medication,
Government,
Therapy,
Biotechnology,
Investigational New Drug,
Sepsis,
Pharmaceutical industry These achievements collectively position Recce on track with its upcoming IND application, underscoring the company's dedication to bringing novel therapies to market swiftly and responsibly.
Key Points:
- These achievements collectively position Recce on track with its upcoming IND application, underscoring the company's dedication to bringing novel therapies to market swiftly and responsibly.
- Recce has been actively pursuing various grant applications and submissions, particularly in government antimicrobial resistance (AMR) initiatives and military and health security.
- Recce delivered a company presentation at the request of the U.S. Biomedical Advanced Research and Development Authority (BARDA), further strengthening its relationship and collaboration with U.S. governmental organizations.
- This acknowledgment highlights the potential of RECCE® compounds to address critical global health challenges posed by antibiotic-resistant bacteria.
Retrieved on:
Wednesday, April 10, 2024
Organization,
Growth,
Global health,
Public,
Research,
ASX,
RCE,
Local government,
United,
AMR,
Ecosystem,
Innovate UK,
Government,
Innovation Professor Dame Sally Davies, former England Chief Medical Officer, hosting a reception with selected organizations offering Recce strategic partnering opportunities in the AMR space
Key Points:
- Professor Dame Sally Davies, former England Chief Medical Officer, hosting a reception with selected organizations offering Recce strategic partnering opportunities in the AMR space
SYDNEY, Australia, April 09, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced its selection by the United Kingdom’s (UK) Government Innovation Agency (Innovate UK) to partake in the prestigious UK Antimicrobial Resistance (AMR) Inward Mission 2024.
- “We are thrilled by the opportunity to collaborate with the UK’s leading AMR experts and institutions and thank the UK government for their support,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
- The UK AMR Inward Mission 2024 will host a comprehensive program, including partnering sessions, visits to world-class AMR infrastructure, and interactions with key opinion leaders.
- The selection of Recce for the UK AMR Inward Mission signifies an important geographic opportunity in its global strategy, particularly in establishing a foothold in the UK’s vibrant AMR research and development ecosystem.
Escherichia coli,
Central Bureau,
Statistics,
Burn,
PCT,
Shingles,
Biotechnology,
Growth,
Disease,
HIV,
Klebsiella pneumoniae,
COVID-19,
Inhalation,
HCMV,
ASX,
RCE,
Recce,
Viral,
Pseudomonas aeruginosa,
Virus,
EBV,
SARS-CoV-2,
Staphylococcus aureus,
Gonorrhea,
Cytomegalovirus,
Ross River virus,
Neisseria meningitidis,
GDP,
Urinary tract infection,
Skin,
Streptococcus pyogenes,
Patent,
Staphylococcus,
Streptococcus pneumoniae,
Simplex,
Infection,
USD,
Administration,
Biology,
Ageing,
Pharmaceutical industry SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.
Key Points:
- SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.
- “We are thrilled to have received this newly granted patent in Israel,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
- Israel’s pharmaceuticals and biotechnology market has a reputation for high R&D spending and an impressive international reach, with world-class export numbers and a growing market value.
- Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).
SYDNEY, Australia, March 22, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced it has been issued a trademark registration for RECCE® from the Canadian Intellectual Property Office, strengthening its global intellectual property (IP) portfolio.
Key Points:
- SYDNEY, Australia, March 22, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced it has been issued a trademark registration for RECCE® from the Canadian Intellectual Property Office, strengthening its global intellectual property (IP) portfolio.
- 1289603 formally assigns RECCE® the Canada Trademark No.
- “We are pleased to receive this newly registered trademark in Canada, building upon those already registered in the world’s largest pharmaceutical markets,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
- The Canada Revenue Agency administers the program, aiming to incentivize businesses to conduct R&D in Canada, encouraging innovation and technological advancements.
“Completing dosing of our latest cohort marks another milestone in our journey toward advancing R327 as a potential frontline treatment for patients with UTIs or urosepsis,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
Key Points:
- “Completing dosing of our latest cohort marks another milestone in our journey toward advancing R327 as a potential frontline treatment for patients with UTIs or urosepsis,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
- “We are dedicated to delivering impactful solutions to combat infectious diseases and improve global health outcomes.”
An Independent Safety Committee will now review and evaluate the comprehensive data from the 4-subject cohort.
- Data from this trial is expected to pave the way for a Phase II trial to establish the potential of R327 as a frontline treatment for patients with UTIs or urosepsis.
- The administration of antibiotics via rapid intravenous infusions is a proven safe and effective method of administration, impacting patient treatment, wait times, and nursing workloads globally.
The next cohort of healthy subjects dosed at 3,000mg over 20 minutes, with the remaining subjects to be dosed over the coming days
Key Points:
- The next cohort of healthy subjects dosed at 3,000mg over 20 minutes, with the remaining subjects to be dosed over the coming days
RECCE® 327 now tested at four infusion times, achieving these timestamps in line with intended future regulatory submissions
SYDNEY, Australia, March 14, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced it dosed the next cohort of healthy subjects at 3,000mg within a fast infusion rate of 20-minutes in a Phase I/II trial evaluating its lead candidate, RECCE® 327 (R327).
- “We're pleased to continue advancing the clinical profile of R327, which has demonstrated safe and efficacious potential against a broad range of antibiotic-resistant pathogens across multiple studies,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
- The Company has established that the dose of 3,000mg, administered at varying infusion times between 15 and 60 minutes, has been proven safe in participants.
- The efficacy of R327 via intravenous administration will be made available at the completion of the Phase I/II trial in line with the study protocol.
Retrieved on:
Wednesday, March 13, 2024
SYDNEY, Australia, March 13, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced a poster presentation of data from a Phase 1 study evaluating the safety of its lead asset, RECCE® 327, at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting taking place March 27-29, 2024, in Colorado Springs, Colorado.
Key Points:
- SYDNEY, Australia, March 13, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced a poster presentation of data from a Phase 1 study evaluating the safety of its lead asset, RECCE® 327, at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting taking place March 27-29, 2024, in Colorado Springs, Colorado.
- Details for the presentation are as follows:
Title: FIH Study of Intravenous RECCE 327: A Novel, Broad Spectrum, Synthetic Anti-Infective
A copy of the poster will be available on Recce’s website after the conclusion of the conference.
Recce received $11.17 million in non-dilutive cash, reflecting R&D rebate credits for FY23/24, in addition to future anticipated R&D applicable expenditure for FY25.
Key Points:
- Recce received $11.17 million in non-dilutive cash, reflecting R&D rebate credits for FY23/24, in addition to future anticipated R&D applicable expenditure for FY25.
- This enables the Company to leverage its R&D expenditure benefits of the past, present, and future R&D applicable expenditure on a here-today basis, as achieved by this agreement.
- “Securing this advanced funding from Endpoints is a testament to the strength of Recce’s scientific platform and the potential of our pipeline,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
- Any surplus to R&D rebates, including around an imminent R&D rebate to FY23, is always that of Recce’s.
